
    
      An open-label, dose escalation, first-in-human, phase 1 clinical study to investigate the
      safety, tolerability and to determine the maximum tolerated dose and recommended phase 2 dose
      of HLX23 (recombinant anti-CD73 humanized monoclonal antibody) in patients with advanced or
      metastatic solid tumors
    
  